(Q37760357)

22 August 2017

1 reference

title

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? (English)

1 reference

non-small-cell lung carcinoma

22 August 2017

main subject

1 reference

1

J C Soria

0 references

author name string

C Massard

series ordinal

2

1 reference

22 August 2017

T Le Chevalier

series ordinal

3

1 reference

22 August 2017

publication date

23 May 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

21

1 reference

22 August 2017

issue

12

1 reference

22 August 2017

page(s)

2324-2332

1 reference

Global cancer statistics, 2002

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Gene expression profiling of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Cytogenetic and molecular aspects of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Therapeutic strategy for treatment of metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Progression-free survival as a surrogate endpoint in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Evaluation of lymph nodes with RECIST 1.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Endpoints for agents that slow tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

The validation of surrogate endpoints in meta-analyses of randomized experiments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Issues in using progression-free survival when evaluating oncology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Individual- and trial-level surrogacy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Progression-free survival is a surrogate for survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Role of sensitivity analyses in assessing progression-free survival in late-stage oncology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Sorafenib for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Emerging therapies in castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

New targets for non-small-cell lung cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Targeted therapy in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Bevacizumab for the treatment of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Targeting angiogenesis in the treatment of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Non-receptor tyrosine kinase inhibitors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Immunotherapy for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Docetaxel in the treatment of advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Neoadjuvant therapy for resectable non-small cell lung cancer with mediastinal lymph node involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

Bevacizumab in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ204

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDQ204

1 reference

22 August 2017

1 reference